HOUSTON, Nov. 11, 2025 /PRNewswire/ — Salarius Pharmaceuticals, Inc. (“Salarius” or the “Company”) (NASDAQ: SLRX) today announced the pricing of an underwritten public offering for gross proceeds of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback